MG-KKR-4-53

MG-KKR-4-53 (also known as GM-4-53) is a novel, highly soluble, non-toxic, and cytostatic tetrahydroisoquinoline (THIQ) derivative developed by researchers at Florida A&M University for the treatment of triple-negative breast cancer (TNBC). Unlike traditional microtubule-targeting agents like paclitaxel, MG-KKR-4-53 acts as a cytostatic agent that halts TNBC cell proliferation without functioning as a spindle poison or impairing tubulin depolymerization. Instead, it arrests the cell cycle at the G2/M phase, downregulates inhibitor of DNA binding (ID) transcripts (ID1, ID3, and ID4), and reduces amphiregulin (AREG) and epiregulin (EREG) expression, which are critical for cell division.

Other names

4-ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)benzamide